Angion Biomedica Corp (ANGN)

NASDAQ
1.06
+0.03(+2.91%)
  • Volume:
    7,569
  • Day's Range:
    1.03 - 1.06
  • 52 wk Range:
    0.98 - 14.18
Earnings results expected tomorrow

ANGN Overview

Prev. Close
1.03
Day's Range
1.03-1.06
Revenue
29.59M
Open
1.06
52 wk Range
0.98-14.18
EPS
-1.08
Volume
7,569
Market Cap
31.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
165,626
P/E Ratio
-
Beta
-
1-Year Change
-90.39%
Shares Outstanding
29,958,840
Next Earnings Date
Aug 11, 2022
What is your sentiment on Angion Biomedica?
or
Vote to see community's results!

Angion Biomedica Corp News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Angion Biomedica Corp Company Profile

Angion Biomedica Corp Company Profile

Employees
71

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellSell
SummaryStrong BuyBuyStrong SellStrong SellStrong Sell
  • It was surprised that it seemed to fail its IPO. It price might fall to penny soon.
    0
    • 😆lol
      0